Trial Profile
Early Alirocumab to Reduce LDL-C in Myocardial Infarction
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 14 Jun 2019
Price :
$35
*
At a glance
- Drugs Alirocumab (Primary) ; Atorvastatin; Ezetimibe
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Acronyms EARLY
- 11 Jun 2019 Planned End Date changed from 1 Jul 2019 to 1 Dec 2021.
- 11 Jun 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Dec 2020.
- 11 Jun 2019 Planned initiation date changed from 1 Jan 2019 to 1 Jan 2020.